Recombinant humanized anti-TNFα monoclonal antibody (Shenzhen Main Luck Pharmaceuticals)

重组人源化抗肿瘤坏死因子α单克隆抗体（深圳万乐药业）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant humanized anti-TNFα monoclonal antibody (Shenzhen Main Luck Pharmaceuticals)
Drug Alias Name重组人源化抗肿瘤坏死因子α单克隆注射液重组人源化抗肿瘤坏死因子α单抗注射液
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, RheumatoidSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (IND)
Highest Status in ChinaDiscontinued
Originator CompaniesShenzhen Main Luck Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesShenzhen Main Luck Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidSpondylitis, Ankylosing

Other Information

ATC CodeN/A
Related LinksN/A